Drugs

Current Cardiac Risk Paradigm: Arrhythmia Risk Assessment During Drug Development without the Thorough QT Study

Meeting information

On July 23, 2013, FDA is conducting a public workshop on Rechanneling the Current Cardiac Risk Paradigm: Arrhythmia Risk Assessment During Drug Development without the Thorough QT Study. The workshop will introduce for discussion a new nonclinical paradigm for assessing Torsade de Pointes (TdP) risk and explore the parameters for an appropriate, strong, nonclinical proarrthymia screening method as an alternative to clinical Thorough QT studies.
 
This website will be updated as meeting materials are developed.

Date: 
July 23, 2013 
Time: 
8:00 a.m. to 6:00 p.m 
Location:
FDA White Oak Campus 10903 New Hampshire Ave.
Building 31, Room 1503A (Great Room)                                                                                   
Silver Spring, MD 20993 
Registration: 
To register for this meeting:
 
 
 
Registration for non FDA attendees will close on July 15, 2013.  

Meeting Materials
 
 

 

Page Last Updated: 12/10/2014
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.